MENU

RLAY Stock Relay Therapeutics (RLAY, $3.08) Moving Average Convergence Divergence (MACD) Histogram turned positive on May 29, 2025

A.I.dvisor
at Tickeron.com
Loading...
RLAY - Relay Therapeutics
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $3.08
Daily change: +$0.13 (+4.41%)
Daily volume: 797.2K
Capitalization: $528M
Industry: Biotechnology
This is a Bullish indicator signaling RLAY's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 42 similar cases where RLAY's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

RLAY's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for RLAY turned positive on May 29, 2025. Looking at past instances where RLAY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where RLAY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on May 28, 2025. You may want to consider a long position or call options on RLAY as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

RLAY moved above its 50-day moving average on May 28, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RLAY crossed bullishly above the 50-day moving average on May 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .

RLAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 142 cases where RLAY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLAY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.713) is normal, around the industry mean (16.282). P/E Ratio (0.000) is within average values for comparable stocks, (59.459). RLAY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (59.524) is also within normal values, averaging (270.467).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RLAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RLAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
399 Binney Street
Phone
+1 617 370-8837
Employees
323
Web
https://www.relaytx.com